E-Horizon 2021 Future Healthcare Industry Summit to Spotlight Cutting-Edge Biopharma Innovations in Shanghai
As in 2020, global biopharmaceutical financing continued to dominate the healthcare sector in the first half of 2021, totaling approximately RMB 191.8 billion, surpassing the combined figures for digital health and medical devices.
Furthermore, according to the "2020 Global Healthcare Industry Capital Report" by VCBeat Research Institute, from 2011 to 2020, among the five major healthcare subsectors—biopharmaceuticals, digital health, medical devices and consumables, pharmaceutical commerce, and healthcare services—biopharmaceuticals consistently ranked first in financing volume due to their large market size and high capital requirements driven by R&D investment, accounting for 40% of the total year after year.
Trends in the Proportion of Total Financing by Healthcare Sub-sectors, 2011–2020
(Image source: VCBeat’s “2020 Global Healthcare Industry Capital Report”)
According to the "2021 China Biopharmaceutical Industry Development Prospect Forecast and Investment Research Report" by VCBeat Institute,China's Biopharmaceutical Industry Market Size to Exceed RMB 4 Trillion in 2022
Biopharmaceuticals have consistently remained at the forefront of the healthcare sector, and their development is inextricably linked to policy support.
In 2020, the Center for Drug Evaluation of the National Medical Products Administration implemented a series of policy reforms concerning the clinical development, regulatory review, and market pricing of innovative drugs.
For example, the National Medical Products Administration (NMPA) revised the Measures for the Administration of Drug Registration, strengthening regulatory oversight across the entire drug lifecycle—from development and market launch to post-marketing management and cancellation of drug registration certificates—and established expedited review and approval pathways for new drugs qualifying as breakthrough therapies, those granted conditional approval, those eligible for priority review, and those subject to special approval.
The three documents released in July 2020, including the “Procedures for the Review of Breakthrough Therapy Drugs (Trial),” clearly define the scope of breakthrough therapy drug designation, the applicable conditions for conditional marketing approval, and the scope of priority review.
The digital transformation of the global biopharmaceutical industry, particularly in new drug development, is accelerating. The discovery of innovative targets peaked in 2020 at 139, and countries are increasingly increasing their R&D investment in cutting-edge therapies such as cell and gene therapy.
Furthermore, it is worth noting that many regions across China are currently building biopharmaceutical industry clusters. Among them, Shanghai has become one of the most influential innovation hubs for the biopharmaceutical industry in China, owing to its relatively complete industrial system, high level of internationalization, and strong R&D and innovation capabilities.
Clearly, whether driven by policy or industry demand, innovation and digitalization have become the central themes in the development of the biopharmaceutical sector. Amid this wave, the primary challenge facing all stakeholders is how to look beyond superficial trends to grasp the essence and truly seize emerging opportunities.
From October 11 to 14, 2021, Shanghai will host China’s first Biopharmaceutical Industry Week. Leveraging the participation of biopharmaceutical industrial parks, internationally renowned enterprises, and investment institutions, the event will feature twenty forums covering topics such as innovative R&D and intelligent manufacturing of pharmaceuticals and medical devices, as well as the role of capital markets in driving industry development.
Among them,The “2021 Future Healthcare Industry Summit,” hosted by E Fund Asset Management Co., Ltd. (hereinafter referred to as “E Fund Asset”) and co-organized by the Shanghai Biomedical Industry Promotion Center, the Shanghai Biomedical Industry Association, the Shanghai Artificial Intelligence Research Institute, China Renaissance Group, GF Securities, CITIC Securities, Haitong Securities, Industrial Securities, and Tianfeng Securities, will also be held on October 12–13 at the Shangri-La Hotel Pudong, Shanghai.
It is reported that,E Fund Asset Management, established in 2013, has set up an independent healthcare investment department, with genomics, digital health, and consumer health as its key focus areas.
At the upcoming “2021 Future Healthcare Industry Summit,” E Fund Asset Management has invited leading scientific experts and renowned entrepreneurs from the fields of gene therapy, gene editing, cell and gene therapy, nucleic acid therapeutics, genomic big data, and medical technology. Under the theme “Collaborating for the Future, Driving Renewal,” participants will explore the future development directions of biopharmaceuticals and medical technology through keynote speeches, roundtable discussions, and other formats.
Additionally, on October 13, E Fund Asset Management separately organized two closed-door discussion sessions: one focusing on nucleic acid testing and the upstream biopharmaceutical supply chain, and the other on the application of information technology tools such as AI and blockchain in new drug development. The events invited numerous distinguished entrepreneurs and industry analysts to deliver thematic presentations and explore cutting-edge topics, including how information technology can facilitate new drug R&D and how biopharmaceutical companies can achieve innovative breakthroughs.
“As the organizer of this event, E Fund Asset Management aims to establish this summit as a platform for exchange and interaction among all industry participants. We sincerely invite everyone to attend and jointly explore the future development trends in the biopharmaceutical sector,” said Wang Hao, Head of the Healthcare Industry at E Fund Asset Management.
The detailed agenda of the conference is as follows:
